Shearwood McClelland, MD
Specialty: Radiation Oncology
Location:UH Cleveland Medical Center
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-286-3900
Biography: Shearwood McClelland, MD
Residency | Radiation Oncology
Radiation Oncology - Indiana University Hospital (2018 - 2022)
Fellowship | Orthopaedic Surgery
Orthopaedic Surgery - New York University Hospital For Joint Diseases (2015 - 2016)
Internship | Neurological Surgery
Neurological Surgery - Lahey Hospital And Medical Center (2012 - 2013)
Fellowship | Neurological Surgery
Neurological Surgery - Boston University Medical Campus (2010 - 2012)
Residency | Neurological Surgery
Neurological Surgery - University Of Minnesota Medical Center - East Bldg (2007 - 2009)
Internship | General Surgery
General Surgery - University Of Minnesota Medical Center - East Bldg (2006 - 2007)
Research Fellowship | Neurological Disorders and Stroke
Neurological Disorders and Stroke - Neurological Institute Of New York (2004 - 2005)
Columbia University College Of Physicians And Surgeons (2004)
Harvard University (2000)
Shearwood McClelland III MD, joins University Hospitals as the Director of Spine Oncology, Department of Radiation Oncology. Dr. McClelland is an internationally recognized physician for his 15-year track record of investigating disparities in healthcare access and his work on radiation-based modalities for treating central nervous system disease, including the first analysis of spine stereotactic body radiation therapy (SBRT) utilization throughout the United States.
He graduated with honors from Harvard College and earned his medical degree from the Columbia University College of Physicians and Surgeons. Dr. McClelland completed his residency at Indiana University and is fellowship-trained in linear accelerator and Gamma Knife stereotactic radiosurgery.
Dr. McClelland’s research involves utilizing hypofractionation to reduce disparities in radiation therapy access facing underrepresented minorities in the United States. He is a four-time winner of the American Society of Clinical Oncology’s Conquer Cancer Foundation Merit Award and a two-time winner of the Radiological Society of North America’s Trainee Research Prize. Dr. McClelland has also received multiple awards, including the Young Oncologist Travel Award from the American Radium Society, the Young Investigator Award from the American Epilepsy Society, the Cone Pevehouse Award from the American Association of Neurological Surgeons, the International Epilepsy Symposium Research Award from the Cleveland Clinic, and the Wilbert C. Jordan Clinical Science Research Award from the Student National Medical Association.
He has presented his work at more than 30 national and international scientific meetings, including the American Society of Clinical Oncology, the American Society for Radiation Oncology, American Radium Society, Radiological Society of North America, Society for Neuro-Oncology, American Epilepsy Society, SpineWeek, American Association of Neurological Surgeons, Congress of Neurological Surgeons, International Epilepsy Symposium, the North American Spine Society, and the International Stereotactic Radiosurgery Society.
Dr. McClelland has published more than 160 articles (including more than 130 first-author publications) in peer-reviewed journals, including The Lancet, The Lancet Oncology, and JAMA Oncology. He is also the creator of the pre-residency peer-reviewed publications (PRP) metric, which has been validated in both radiation oncology and neurosurgery as being associated with the subsequent resident choice of academic versus private practice career, and the Navigator-Assisted Hypofractionation (NAVAH) program designed to utilize patient navigation to reduce radiation therapy access disparities.
Dr. McClelland serves on multiple national/international editorial boards and is a member of the NRG Oncology Brain Tumor Scientific Core Committee, American Radium Society Appropriate Use Criteria Brain Malignancies Panel, NRG Oncology Health Disparities Scientific Core Committee, American Society of Clinical Oncology Trainee & Early Career Advisory Group, SWOG CNS Working Group Committee, American Society for Radiation Oncology Health Equity Diversity and Inclusion (HEDI)–Association for Directors of Radiation Oncology Programs (ADROP) Collaborative Group, and co-chair of the NRG Oncology Rural Health Research Special Interest Group.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Shearwood McClelland did not disclose any Outside Relationships with Industry.